EMPACT‐MI was the first prospective randomized controlled trial to investigate the effect of SGLT2 inhibitors on clinical outcomes after acute MI in a cohort with and without T2DM.6 The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.